Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE1A | P54750 | 3/20 | 0.44 |
| ▸ | PDE1B | Q01064 | 3/20 | 0.44 |
| ▸ | PDE1C | Q14123 | 3/20 | 0.44 |
| ▸ | MPO | P05164 | 3/20 | 0.44 |
| ▸ | ATM | Q13315 | 5/20 | 0.43 |
| ▸ | MEN1 | O00255 | 5/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | RAC1 | P63000 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31037076 | 0.85 | MPO (0.44) | PDE1APDE1BPDE1CMPOATM | |
| SCHEMBL25302065 | 0.80 | ATM (0.49) | ATMMEN1KMT2AKDM4EMAPT | |
| SCHEMBL29405109 | 0.80 | ATM (0.49) | ATMMEN1KMT2AKDM4EMAPT | |
| SCHEMBL29404957 | 0.79 | KDM4E (0.42) | PDE1APDE1BPDE1CMPOKDM4E | |
| SCHEMBL25256662 | 0.79 | KDM4E (0.42) | PDE1APDE1BPDE1CMPOKDM4E | |
| SCHEMBL25257906 | 0.78 | ALDH1A1 (0.56) | MPOATMMEN1KMT2AKDM4E | |
| SCHEMBL29404485 | 0.78 | ALDH1A1 (0.56) | MPOATMMEN1KMT2AKDM4E | |
| SCHEMBL25254447 | 0.77 | MPO (0.44) | PDE1APDE1BPDE1CMPOATM | |
| SCHEMBL29405726 | 0.77 | MPO (0.44) | PDE1APDE1BPDE1CMPOATM | |
| SCHEMBL25253315 | 0.75 | LMNA (0.52) | ATMMEN1KMT2AKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12570613-B2 | Imidazoquinoline or benzoindazolone compound and intermediate for preparing same | LMITO THERAPEUTICS INC. (KR) | 2026-03-10 | — | — | US | disclosed |
| US-20240034719-A1 | IMIDAZOQUINOLINE OR BENZOINDAZOLONE COMPOUND AND INTERMEDIATE FOR PREPARING SAME | LMITO THERAPEUTICS INC. (KR) | 2024-02-01 | — | — | US | disclosed |
| EP-4212530-A1 | IMIDAZOLQUINOLINE OR BENZOINDAZOLONE COMPOUND AND INTERMEDIATE FOR PREPARING SAME | Lmito Therapeutics Inc. (KR) | 2023-07-19 | — | — | EP | disclosed |
| CN-115956071-A | Imidazoquinoline or benzindazolone compounds and intermediates for their preparation | LMITO药业株式会社 | 2023-04-11 | — | — | CN | disclosed |
| WO-2022039460-A1 | IMIDAZOLQUINOLINE OR BENZOINDAZOLONE COMPOUND AND INTERMEDIATE FOR PREPARING SAME | 주식회사 엘마이토테라퓨틱스 | 2022-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240034719-A1 | IMIDAZOQUINOLINE OR BENZOINDAZOLONE COMPOUND AND INTERMEDIATE FOR PREPARING SAME | NQO1, NFE2L2, KEAP1 | PDE1A 2846/4885PDE1B 3600/4885PDE1C 3210/4885 |
| US-12570613-B2 | Imidazoquinoline or benzoindazolone compound and intermediate for preparing same | NQO1, CBR1, NFE2L2 | PDE1A 4033/4885PDE1B 4246/4885PDE1C 4262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.